Pharming Group (NASDAQ:PHAR) Releases Earnings Results

Pharming Group (NASDAQ:PHAR) issued its earnings results on Thursday. The company reported $0.05 earnings per share for the quarter, missing the consensus estimate of $0.07 by ($0.02), Zacks reports. Pharming Group had a negative return on equity of 7.65% and a negative net margin of 6.09%. Pharming Group updated its FY 2025 guidance to EPS.

Pharming Group Stock Up 14.5 %

Shares of Pharming Group stock traded up $1.12 on Thursday, hitting $8.86. 9,496 shares of the company’s stock traded hands, compared to its average volume of 6,128. The stock has a market cap of $602.75 million, a P/E ratio of -34.08 and a beta of -0.10. The firm’s 50-day moving average is $9.05 and its 200 day moving average is $8.57. The company has a quick ratio of 2.76, a current ratio of 3.53 and a debt-to-equity ratio of 0.41. Pharming Group has a 52-week low of $6.65 and a 52-week high of $11.80.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on PHAR shares. HC Wainwright restated a “buy” rating and issued a $37.00 price target on shares of Pharming Group in a report on Tuesday, December 17th. Jefferies Financial Group initiated coverage on shares of Pharming Group in a research note on Monday, December 9th. They issued a “buy” rating and a $14.00 target price for the company.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.